(CercleFinance.com) – Pfizer and BioNTech have announced that they have finalized a submission to the European Medicines Agency (EMA) for a booster dose of a bivalent COVID-19 vaccine suitable for Omicron BA.4/BA.5 for people aged 12 and over.
Preclinical data showed that a booster dose of the adapted bivalent vaccine Omicron BA.4/BA.5 from Pfizer and BioNTech generated a strong neutralizing antibody response against the Omicron BA.1, BA.2 and BA variants. 4/BA.5, as well as against the original wild-type strain.
The companies also provided safety data from clinical trials evaluating several variant-matched vaccine candidates based on prior variants of concern (eg, Alpha, Beta, and Delta variants).
Pfizer and BioNTech also filed an application with the EMA for the bivalent COVID-19 vaccine suitable for Omicron BA.1 in July, which is currently under review by the Agency.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
